Clonidine Hydrochloride
CLONIDINE HYDROCHLORIDE TABLETS USP
809d8d33-9459-4e74-8cd2-5f5a9670cb95
HUMAN PRESCRIPTION DRUG LABEL
Feb 6, 2013
Richmond Pharmaceuticals, Inc.
DUNS: 043569607
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Clonidine Hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (6)
Clonidine Hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (7)
Clonidine Hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (9)
Drug Labeling Information
ADVERSE REACTIONS SECTION
ADVERSE REACTIONS
Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100.
The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride tablets USP, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.
**Body as a Whole:**Fatigue, fever, headache, pallor, weakness, and withdrawal syndrome. Also reported were a weakly positive Coombs' test and increased sensitivity to alcohol.
**Cardiovascular:**Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms, palpitations, Raynaud's phenomenon, syncope, and tachycardia. Cases of sinus bradycardia and atrioventricular block have been reported, both with and without the use of concomitant digitalis.
**Central Nervous System:**Agitation, anxiety, delirium, delusional perception, hallucinations (including visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia, restlessness, sleep disorder, and vivid dreams or nightmares.
**Dermatological:**Alopecia, angioneurotic edema, hives, pruritus, rash, and urticaria.
**Gastrointestinal:**Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and vomiting.
**Genitourinary:**Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention.
**Hematologic:**Thrombocytopenia.
**Metabolic:**Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase, and weight gain.
**Musculoskeletal:**Leg cramps and muscle or joint pain.
**Oro-otolaryngeal:**Dryness of the nasal mucosa.
**Ophthalmological:**Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of eyes.